



Ms Melissa Kostopoulos  
Adviser, Listings Compliance (Melbourne)  
ASX Compliance Pty Ltd  
Level 4, Rialto North Tower  
525 Collins Street  
Melbourne VIC 3000

By Email: melissa.kostopoulos@asx.com.au

26 October 2020

**CLINUVEL PHARMACEUTICALS LTD (ASX:CUV) - REQUEST FOR TRADING HALT**

Dear Ms Kostopoulos,

Pursuant to Listing Rule 17.1, Clinuvel Pharmaceuticals Ltd ACN 089 644 119 (CUV) requests a trading halt with respect to its ordinary shares listed on the Australian Securities Exchange (ASX).

The trading halt is requested by CUV pending a material announcement to the market regarding a decision by a regulatory authority regarding its evaluation of SCENESSE® (afamelanotide 16mg) to treat erythropoietic protoporphyria (EPP). The trading halt is necessary as otherwise trading in CUV's securities might occur whilst the market as a whole is not reasonably informed.

CUV requests the trading halt to last until the earlier of CUV releasing an announcement in relation to the decision by the regulatory authority or until the commencement of trade on Wednesday 28th October 2020.

CUV is not aware of any reason why the trading halt should not be granted by the ASX, nor is it aware of any other information that is necessary to inform the market about the trading halt.

Yours respectfully,

A handwritten signature in blue ink, appearing to read "D. Keamy", with a small blue mark to the right.

Mr Darren Keamy  
Company Secretary  
Clinuvel Pharmaceuticals Ltd